Selective replication of E1B55K-deleted adenoviruses depends on enhanced E1A expression in cancer cells

Cancer Gene Therapy

Volumn 13, Issue 6, 2006, Pages 572-583

  Zheng, X ^a   Rao, X M ^a   Snodgrass, C L ^a   McMasters, K M ^a   Zhou, H S ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Adenovirus; Cell cycle; E1 genes; Oncolysis; Replication

Indexed keywords

ANTINEOPLASTIC AGENT; E1A PROTEIN; ONYX 015; PROTEIN E1B55K; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS DNA;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL KILLING; CONTROLLED STUDY; DNA FLANKING REGION; E1A GENE; EIB55K GENE; GENE; GENE DELETION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; VIRAL GENE THERAPY; VIRUS GENE; VIRUS REPLICATION; VIRUS RESISTANCE;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ADENOVIRUS E2 PROTEINS; CELL CYCLE; CELL LINE, TUMOR; GENE DELETION; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; PROMOTER REGIONS (GENETICS); UP-REGULATION; VIRUS REPLICATION;

EID: 33646760641     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700923     Document Type: Article

References (55)

1. Zhao T, Rao XM, Xie X, Li L, Thompson TC, McMasters KM et al. Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo. Cancer Res 2003; 63: 3073-3078.
2. Rao XM, Tseng MT, Zheng X, Dong Y, Jamshidi-Parsian A, Thompson TC et al. E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells. Cancer Gene Ther 2004; 11: 585-593.
3. Hallenbeck PL, Chang YN, Hay C, Golightly D, Stewart D, Lin J et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999; 10: 1721-1733.
4. Kim J, Lee B, Kim JS, Yun CO, Kim JH, Lee YJ et al. Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells. Cancer Lett 2002; 180: 23-32.
5. Takahashi M, Sato T, Sagawa T, Lu Y, Sato Y, Iyama S et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther 2002; 5: 627-634.
6. Ren XW, Liang M, Meng X, Ye X, Ma H, Zhao Y et al. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma. Cancer Gene Ther 2005 (in press).
7. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000; 106: 763-771.
8. Hernandez-Alcoceba R, Pihalja M, Wicha MS, Clarke MF. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. Hum Gene Ther 2000; 11: 2009-2024.
9. Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P, Fisher PB. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci USA 2005; 102: 14034-14039.
10. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 2005; 11: 1483-1489.
11. Fuerer C, Iggo R. Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Therapy 2002; 9: 270-281.
12. Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 2002; 62: 4663-4670.
13. Banerjee NS, Rivera AA, Wang M, Chow LT, Broker TR, Curiel DT et al. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures. Mol Cancer Ther 2004; 3: 437-449.
14. Peter I, Graf C, Dummer R, Schaffner W, Greber UF, Hemmi S. A novel attenuated replication-competent adenovirus for melanoma therapy. Gene Therapy 2003; 10: 530-539.
15. Liu Y, Ye T, Sun D, Maynard J, Deisseroth A. Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma. Hum Gene Ther 2004; 15: 637-647.
16. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559-2563.
17. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999; 59: 4200-4203.
18. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61: 517-525.
19. Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 2001; 61: 5453-5460.
20. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61: 7464-7472.
21. Dilley J, Reddy S, Ko D, Nguyen N, Rojas G, Working P et al. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther 2005; 12: 715-722.
22. Haviv YS, Curiel DT. Engineering regulatory elements for conditionally-replicative adeno-viruses. Curr Gene Ther 2003; 3: 357-385.
23. Nettelbeck DM. Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis. Anticancer Drugs 2003; 14: 577-584.
24. Kanerva A, Hemminki A. Modified adenoviruses for cancer gene therapy. Int J Cancer 2004; 110: 475-480.
25. Post DE, Khuri FR, Simons JW, Van Meir EG. Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 2003; 14: 933-946.
26. Barker DD, Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987; 156: 107-121.
27. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
28. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639-645.
29. Rogulski KR, Freytag SO, Zhang K, Gilbert JD, Paielli DL, Kim JH et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 2000; 60: 1193-1196.
30. Dix BR, Edwards SJ, Braithwaite AW. Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? J Virol 2001; 75: 5443-5447.
31. Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe MJ et al. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 2002; 62: 764-772.
32. Hobom U, Dobbelstein M. E1B-55-kilodalton protein is not required to block p53-induced transcription during adenovirus infection. J Virol 2004; 78: 7685-7697.
33. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6: 611-623.
34. Steegenga WT, Riteco N, Bos JL. Infectivity and expression of the early adenovirus proteins are important regulators of wild-type and DeltaE1B adenovirus replication in human cells. Oncogene 1999; 18: 5032-5043.
35. Edwards SJ, Dix BR, Myers CJ, Dobson-Le D, Huschtscha L, Hibma M et al. Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J Virol 2002; 76: 12483-12490.
36. Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M et al. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87: 1973-1977.
37. Farshid M, Tabor E. Expression of oncogenes and tumor suppressor genes in human hepatocellular carcinoma and hepatoblastoma cell lines. J Med Virol 1992; 38: 235-239.
38. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990; 10: 5772-5781.
39. Chandar N, Billig B, McMaster J, Novak J. Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer 1992; 65: 208-214.
40. Morsy MA, Alford EL, Bett A, Graham FL, Caskey CT. Efficient adenoviral vector mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes. J Clin Invest 1993; 92: 1580-1586.
41. Zhou H, Beaudet A. A new vector system with inducible cell line E2T for production of safer and higher titer adenoviral vectors. Virology 2000; 275: 348-357.
42. Zhou H, O'Neal W, Morral N, Beaudet AL. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J Virol 1996; 70: 7030-7038.
43. Sarnow P, Sullivan CA, Levine AJ. A monoclonal antibody detecting the adenovirus type 5-E1b-58kD tumor antigen: characterization of the E1b-58kD tumor antigen in adenovirus-infected and -transformed cells. Virology 1982; 120: 510-517.
44. Graham FL. Manipulation of adenovirus vectors. In: Murray EJ (ed). Methods in Molecular Biology, Vol. 7. The Humana Press Inc.: Clifton, NJ, 1991, pp 109-128.
45. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802-8806.
46. Shenk T. Adenoviridae: the viruses and their replication. In: Knipe DM, Howley PM (eds). Fields Virology, Vol. 2. Lippincott Williams & Wilkins: Philadelphia, PA, 2001, pp 2265-2300.
47. Osborne TF, Gaynor RB, Berk AJ. The TATA homology and the mRNA 5′ untranslated sequence are not required for expression of essential adenovirus E1A functions. Cell 1982; 29: 139-148.
48. Osborne TF, Berk AJ. Far upstream initiation sites for adenovirus early region 1A transcription are utilized after the onset of viral DNA replication. J Virol 1983; 45: 594-599.
49. Frisch SM, Mymryk JS. Adenovirus-5 E1A: paradox and paradigm. Nat Rev Mol Cell Biol 2002; 3: 441-452.
50. Ries S, Korn WM. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer 2002; 86: 5-11.
51. Biederer C, Ries S, Brandts CH, McCormick F. Replication-selective viruses for cancer therapy. J Mol Med 2002; 80: 163-175.
52. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7: 781-787.
53. O'Shea CC, Soria C, Bagus B, McCormick F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 2005; 8: 61-74.
54. Mal A, Poon RY, Howe PH, Toyoshima H, Hunter T, Harter ML. Inactivation of p27Kip1 by the viral E1A oncoprotein in TGFbeta-treated cells. Nature 1996; 380: 262-265.
55. Whalen SG, Marcellus RC, Whalen A, Ahn NG, Ricciardi RP, Branton PE. Phosphorylation within the transactivation domain of adenovirus E1A protein by mitogen-activated protein kinase regulates expression of early region 4. J Virol 1997; 71: 3545-3553.